A study of the action of risperidone at 5-HT2A receptors
Risperidone is an ‘atypical’ antipsychotic and is approved by the USFDA mainly for the treatment of schizophrenia and symptoms of bipolar disorder. Risperidone (an SDA or serotonin-dopamine antagonist) has ~20-fold higher affinity at 5-HT2A receptors over dopamine D2 receptors, which makes it more e...
| Main Author: | |
|---|---|
| Format: | Others |
| Published: |
VCU Scholars Compass
2016
|
| Subjects: | |
| Online Access: | http://scholarscompass.vcu.edu/etd/4112 http://scholarscompass.vcu.edu/cgi/viewcontent.cgi?article=5174&context=etd |